Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 with olaparib with or without bevacizumab in advanced solid tumors
NL-OMON55669Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab, olaparib and bevacizumab in Nonhematologic neoplasms, small cell lung cancer (SCLC), breast cancer and 2 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Disease control rate at 12 weeks, Overall response rate in BRCA-mutated cancer expansion cohort and 4 more. Started Jun 2016; status: active, not recruiting.
02
Drugs
durvalumabolaparibbevacizumab
03
Conditions
Nonhematologic neoplasmssmall cell lung cancer (SCLC)breast cancerovarian cancergastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON55669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55669.